

Spring cooling for SPACs

Investment strategy insights

Authors: Jason Draho, Head Asset Allocation Americas, UBS Financial Services Inc. (UBS FS); Vincent Amaru, Investment Strategist Americas

- The SPAC market has cooled significantly over the past month, after exhibiting frothy conditions in February. New SPAC supply has slowed considerably, the number of acquisitions has moderated, and share prices are down collectively over 20%, with some prices down more than 50%.
- Pricing patterns around SPAC merger announcement dates suggest that the overheating in February was due to investor speculation, much of which appears to have been flushed out of the market. The result is healthier market conditions than a few months ago.
- The near-term outlook depends on investors' willingness to participate, SPAC share prices continuing to hover around USD 10, and the supply of acquisition targets, all of which are downside risks. But SPAC pricing is starting to reflect these risks. Still, we caution investors to become well informed about SPACs before investing in them.

Note: In this version, Fig. 1 and Fig. 2 now represent SPAC issuance based on those that are currently trading. The previous version had also included SPACs that had been priced but were still pending.

Temperatures are rising as spring blooms, but there's been significant cooling in the SPAC market in recent weeks after a torridly hot winter. Thus far, it's more moderation from unsustainable levels than it is falling off of a cliff. SPAC return patterns over the last six months also suggest fairly convincingly that speculation, not fundamentals, was driving prices. Consequently, SPACs—special purpose acquisition companies—became a quintessential “buy the rumor, sell the news” asset. But that phase appears to have passed and SPACs begin 2Q with more realistic expectations than at the start of the year. Such a sentiment reversal isn't surprising, as [we outlined](#) two months ago that SPACs were exhibiting bubble-like characteristics and growing pains were likely, although not necessarily this soon.

Taking out the market frothiness actually improves SPACs' investment outlook, which continues to benefit from a favorable equity market environment. But SPACs are vulnerable to additional challenges in the months ahead, including many that may be unable to complete a merger and poor returns for at least some that do. Investors should also be well informed about SPACs before investing, even if the share price has declined below the USD 10 redemption price. While that creates a tempting arbitrage opportunity, poor liquidity and deal uncertainty are risks that need to be closely monitored. Looking through this spring cleaning of the SPACs market, we continue to think that they will be a fixture in equity capital markets over the long term, but maybe only after experiencing more growing pains.


This report has been prepared by UBS Financial Services Inc. (UBS FS). Please see important disclaimers and disclosures at the end of the document.

What happened?

In March there was a clear slowdown in the supply of new SPACs and merger announcements, and most notably there were steep declines in SPAC share prices, with many even struggling to stay above USD 10.

First on supply: New SPACs started coming almost immediately in January and maintained a scorching pace until mid-March. The 283 SPAC IPOs in 1Q raised USD 93bn, totals greater than for all of 2020 (Fig. 1).


Fig. 1: SPAC supply in 1Q surpassed 2020 totals...



Source: Bloomberg, UBS, as of 31 March 2021

But starting in early March, the weekly number of new SPACs and the capital raised have trended down, with only five SPACs in the week of 29 March (Fig. 2).


Fig. 2: ...but activity did slow into quarter end



Source: Bloomberg, UBS, as of 2 April 2021

Supply moderation was inevitable because the 1Q pace is unsustainable for a full year. By comparison, conventional IPO supply didn't have a clear trend in 1Q, which was strong with 69 IPOs raising USD 27.5bn (Fig. 3). But USD 3.6bn of expected IPO supply was withdrawn, one of the highest quarterly totals in recent years, highlighting that moderation in new equity supply was broad-based.


Fig. 3: IPO supply was significant and consistent



Source: Bloomberg, UBS, as of 2 April 2021

Merger announcements also slowed in March, with 28 new deals versus 41 in February (Fig. 4).

Fig. 4: SPAC merger announcements fell in March




Source: Dealogic, UBS, as of 31 March 2021

The total enterprise value of these mergers is roughly USD 211bn, already exceeding the 81 “de-SPAC” mergers in 2020 worth USD 148bn in value. Some of this slowdown is due to time constraints among SPAC merger advisors, as there are limits to how many deals they can work on at any point in time. But the pace of SPAC mergers is more likely to hold up compared to the supply of new SPACs because there are already over 400 SPAC sponsors searching for acquisitions, and they are incentivized to close deals.

Share price performance is where SPACs have experienced the biggest tumble. For the SPAC market overall, the decline began in mid-February, with the SPAK and IPOX indexes both down over 20% peak-to-trough, and they’re barely off their lows over the past month (Fig. 5). Within this cohort of post-merger SPACs, there are some down over 40%. Conventional IPOs also fell over 20% from their February peak, measured by the Renaissance IPO ETF, but have rallied modestly off the lows.


Fig. 5: SPACs are still down over 20% from their February peaks



Source: Bloomberg, UBS, as of 6 April 2021

Price weakness has extended to pre-merger announcement SPACs. Most striking is that many are trading below USD 10, the price at which SPAC shareholders have the option to redeem their shares prior to the merger, thereby presenting an arbitrage opportunity. Yet 36% of all SPAC IPOs in March were trading below USD 10 five days after their IPO, compared to none and 3% of SPACs in January and February, respectively (Fig. 6). The bulk of these SPACs were issued later in March, with 15 of the 18 SPACs issued the week of 22 March closing that Friday at or below USD 10.

Fig. 6: Over a third of SPACs that IPO'd in March were trading below USD 10




Source: Dealogic, Bloomberg, UBS, as of 31 March 2021

Why did the SPAC market cool?

There are both fundamental and investor-sentiment reasons why the SPAC market has cooled so notably and quickly, with the latter being the most significant. The fundamental factor is higher rates—the 10-year Treasury yield is up 77 basis points year-to-date, with the majority (47bps) occurring over four weeks in February and March. During this period, the Nasdaq 100 fell nearly 11% peak-to-trough, while the SPAC and IPO indexes were down over 20%. These declines make sense because expensive stocks are very sensitive to even small rate changes.

Fig. 7: Small rate increases matter a lot for expensive stocks

Estimated valuation impact from higher rates for a stock with a 40 P/E multiple




Source: Bloomberg, UBS, as of 6 April 2021

A 10bps rate rise should cause a 4% price decline for a stock with a 40 P/E multiple, all else equal, based on a simple perpetuity formula. The higher the rate rise, the bigger the price hit: A 30bps rate rise lowers the value by 10%, whereas it falls 22% after a 70bps increase (Fig. 7).

The rate rise may have triggered a sell-off in SPACs, but investor euphoria and rampant speculation made them especially vulnerable. The evolving patterns of SPAC share prices around merger announcements illustrate this point. Absent any news about a potential target, SPAC share prices shouldn't rise much above the USD 10 offer price until the merger is announced. Yet in 4Q the average SPAC price rose nearly 10% in the period from 30 to two days prior to the merger announcement (Fig. 8). But then this pre-announcement run-up increased to nearly 15% in January and then peaked at 23% in February before turning negative in March.

Fig. 8: SPACs were rising on merger rumors, selling on actual news




Source: Dealogic, Bloomberg, UBS, as of 6 April 2021. T = merger announcement date

In effect, investors were buying on rumors of a deal, which is why the average announcement “pop”—the return right around the announcement—was actually higher in January (29%) than it was in February (15%). This buying on rumor pulled forward returns, leaving less reason for the share price to pop on announcement. But there was also selling on the news in February, as SPAC shares were down nearly 10% on average in the two weeks after the pop. This selling the merger news is in contrast to the almost 20% average return post-announcement for deals in 4Q.

All told, these merger announcement return patterns show how investor enthusiasm for SPACs started growing late in 2020, accelerated in early 2021 to the point of exuberant speculation, and then cooled very quickly once prices came down sharply over a short period. At this point, sentiment toward SPACs has chilled, but interest could easily pick up again.

To that point, pricing for conventional IPOs has also eased, as evidenced by their first-day returns averaging 50% in January, 40% in February, and 23% in March (Fig. 9). This decline in the monthly averages toward the long-term average first-day return shows that the IPO market has pulled back from its hot status to start the year, but it is still a strong market.

Fig. 9: IPO first-day returns moderating, but still high



Source: Bloomberg, UBS, as of 31 March 2021. Only includes US IPOs greater than USD 100mn on offer

What's the outlook?

The cooling of SPACs from their white-hot status in February to something more temperate is a healthy correction from a long-term perspective, but there is a risk of a deeper market chill in the near term. In our "[SPACs in 2021](#)" report, we identified a number of aspects of the market that would influence how it evolved. Three that are most pertinent right now are: the risk of investors not willing to participate in SPACs, the SPAC share price around the merger date, and the supply of potential acquisition targets.

Investor participation: The ultimate determinant for investor participation in SPACs is performance—if expected risk-adjusted returns are poor, investors won't participate, bringing the market to a halt. The three

main investor types in SPACs have been hedge funds and arbitrage investors in the IPO, institutional investors participating in PIPEs (private investments in public equity) at the merger, and retail investors buying shares or warrants after and increasingly before the SPAC merger announcement.

The economics are still attractive for arbitrage investors in the IPO, but institutional and especially retail investor appetite for SPACs is at risk. The exuberance for SPACs evident in the merger announcement returns is largely attributable to retail investors. Thus, the recent cooling suggests diminished retail interest. But it's not just SPACs that are being impacted by shifting retail activity. Overall retail trading in single stocks and options on single stocks has declined over the last six weeks. This may be temporary, but as the economy fully opens, retail participation may revert closer to pre-pandemic levels. Interest from institutional investors is less fickle, but their constraint may be the amount of capital they have committed to PIPEs is less than what SPAC sponsors will require to complete every potential merger.

Share price at the merger: SPAC share prices hovering below, or even just above, USD 10 is a risk for the long-term success of SPACs post-merger. With share prices that low, the redemption rate for pre-merger investors will likely be higher, depriving the sponsor and post-merger company of that capital and increasing the need to attract new investors, whether institutional via a PIPE or retail investors. That will be a harder sell given recent performance. This type of dynamic can create a negative feedback loop that perpetuates poor SPAC performance.

Supply of potential targets: There are currently 432 SPAC sponsors searching for acquisition targets. For comparison, there were 56 completed SPAC mergers in 2020 and so far in 2021 there are 24 completed mergers and another 83 deals announced but still pending. In other words, the amount of deal activity has to more than double over the next 12 to 18 months in order for all of these SPACs to do a deal. Many won't as the supply of desirable targets that are ready to be public companies is likely lower than the demand. The rising risk of not completing a deal should weigh on their share prices, as already appears to be the case.

These factors together imply downside risk in the near term, but current SPAC pricing is starting to more accurately reflect these risks, and as a result the risk-return for SPACs has improved. A continued slowdown in new supply would also help the market to work through the

existing glut of SPACs searching for deals, alleviating some of the downward share price pressure. None of this changes our long-term view that SPACs will remain a lasting vehicle in equity capital markets. The maturation and institutionalization is the key to this outlook, and this process hasn't been impacted by the euphoria and cooling that the market has experienced over the past six months.

The takeaway for investors is to [remain cautious and become well informed](#) about SPACs before investing in them. The past two months have demonstrated that investors can lose a lot on SPACs, even when they have the redemption option. We still think that investing in a diversified portfolio of SPACs at the IPO offers the best risk-return trade-off because of the redemption option and upside optionality through warrants. Investors who don't participate in the SPAC IPO should wait until the merger target is at least announced and can be evaluated, and now perhaps also wait until the "selling on the news" is complete.

Appendix

UBS Chief Investment Office's ("CIO") investment views are prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS").

The investment views have been prepared in accordance with legal requirements designed to promote the **independence of investment research**.

Generic investment research – Risk information:

This publication is **for your information only** and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein does not constitute a personal recommendation or take into account the particular investment objectives, investment strategies, financial situation and needs of any specific recipient. It is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any forecasts, estimates and market prices indicated are current as of the date of this report, and are subject to change without notice. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria. In no circumstances may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees. By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or otherwise rely on any of the information for any of the above purposes. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instruments in the capacity of principal or agent, or provide any other services or have officers, who serve as directors, either to/for the issuer, the investment instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities) made by UBS and its employees may differ from or be contrary to the opinions expressed in UBS research publications. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is not suitable for every investor as there is a substantial risk of loss, and losses in excess of an initial investment may occur. Past performance of an investment is no guarantee for its future performance. Additional information will be made available upon request. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information.

Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in general or with reference to specific client's circumstances and needs. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein.

This material may not be reproduced or copies circulated without prior authority of UBS. Unless otherwise agreed in writing UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS accepts no liability whatsoever for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. For information on the ways in which CIO manages conflicts and maintains independence of its investment views and publication offering, and research and rating methodologies, please visit www.ubs.com/research. Additional information on the relevant authors of this publication and other CIO publication(s) referenced in this report; and copies of any past reports on this topic; are available upon request from your client advisor.

Options and futures are not suitable for all investors, and trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "Characteristics and Risks of Standardized Options". You may read the document at <https://www.theocc.com/about/publications/character-risks.jsp> or ask your financial advisor for a copy.

Investing in structured investments involves significant risks. For a detailed discussion of the risks involved in investing in any particular structured investment, you must read the relevant offering materials for that investment. Structured investments are unsecured obligations of a particular issuer with returns linked to the performance of an underlying asset. Depending on the terms of the investment, investors could lose all or a substantial portion of their investment based on the performance of the underlying asset. Investors could also lose their entire investment if the issuer becomes insolvent. UBS Financial Services Inc. does not guarantee in any way the obligations or the financial condition of any issuer or the accuracy of any financial information provided by any issuer. Structured investments are not traditional investments and investing in a structured investment is not equivalent to investing directly in the underlying asset. Structured investments may have limited or no liquidity, and investors should be prepared to hold their investment to maturity. The return of structured investments may be limited by a maximum gain, participation rate or other feature. Structured investments may include call features and, if a structured investment is called early, investors would not earn any further return and may not be able to reinvest in similar investments with similar terms. Structured investments include costs and fees which are generally embedded in the price of the investment. The tax treatment of a structured investment may be complex and may differ from a direct investment in the underlying asset. UBS Financial Services Inc. and its employees do not provide tax advice. Investors should consult their own tax advisor about their own tax situation before investing in any securities.

Important Information About Sustainable Investing Strategies: Sustainable investing strategies aim to consider and incorporate environmental, social and governance (ESG) factors into investment process and portfolio construction. Strategies across geographies and styles approach ESG analysis and incorporate the findings in a variety of ways. Incorporating ESG factors or Sustainable Investing considerations may inhibit the portfolio manager's ability to participate in certain investment opportunities that otherwise would be consistent with its investment objective and other principal investment strategies. The returns on a portfolio consisting primarily of sustainable investments may be lower or higher than portfolios where ESG factors, exclusions, or other sustainability issues are not considered by the portfolio manager, and the investment opportunities available to such portfolios may differ. Companies may not necessarily meet high performance standards on all aspects of ESG or sustainable investing issues; there is also no guarantee that any company will meet expectations in connection with corporate responsibility, sustainability, and/or impact performance.

External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.

USA: Distributed to US persons by UBS Financial Services Inc., UBS Securities LLC or UBS Swiss Financial Advisers AG, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliarios Ltda, UBS Asesores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. **UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.**

For country information, please visit ubs.com/cio-country-disclaimer-gr or ask your client advisor for the full disclaimer.

Version C/2020. CIO82652744

© UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.